Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional

This grant aims to create PBPK models for long-acting injectable suspensions and implants, predicting drug release by linking formulation attributes to in-vivo performance.

HHS-FDA$300,000Forecasted

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

This grant aims to improve prediction of food/drug interactions for high-risk oral drugs by using a lab model that mimics the gut to assess drug performance.

HHS-FDA$500,000Forecasted

Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed

This grant seeks to develop AI/ML models using real-world data to monitor clinical outcomes when patients switch between complex generics and brand-name drugs.

HHS-FDA$300,000Forecasted

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

This grant supports research to optimize and advance genomic and biologic therapies for Alzheimer’s-related dementias, from preclinical development through early clinical evaluation.

HHS-NIH11Forecasted Nov 10, 2026· 15d$6,000,000Forecasted

Discovery of in vivo Chemical Probes for the Nervous System

This grant will fund research to discover and optimize new small-molecule chemical probes for novel brain targets to advance understanding of nervous system diseases.

HHS-NIH11Due Mar 5, 2027